BRPI0408284B8 - compostos derivados de ftalazinona, seu uso e composição farmacêutica compreendendo os mesmos - Google Patents

compostos derivados de ftalazinona, seu uso e composição farmacêutica compreendendo os mesmos

Info

Publication number
BRPI0408284B8
BRPI0408284B8 BRPI0408284A BRPI0408284A BRPI0408284B8 BR PI0408284 B8 BRPI0408284 B8 BR PI0408284B8 BR PI0408284 A BRPI0408284 A BR PI0408284A BR PI0408284 A BRPI0408284 A BR PI0408284A BR PI0408284 B8 BRPI0408284 B8 BR PI0408284B8
Authority
BR
Brazil
Prior art keywords
crxry
optionally substituted
pharmaceutical composition
phthalazinone derivatives
nrx
Prior art date
Application number
BRPI0408284A
Other languages
English (en)
Inventor
Ashworth Alan
Kerrigan Frank
Cameron Murray Smith Graeme
Timothy Williams Matthews Ian
Allan Menear Keith
Morrison Barr Martin Niall
Philip Jackson Stephen
M Loh Junior Vincent
Fan Cockcroft Xiao-Ling
Original Assignee
Kudos Pharm Ltd
Maybridge Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32996122&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0408284(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0305681.9A external-priority patent/GB0305681D0/en
Application filed by Kudos Pharm Ltd, Maybridge Ltd filed Critical Kudos Pharm Ltd
Publication of BRPI0408284A publication Critical patent/BRPI0408284A/pt
Publication of BRPI0408284B1 publication Critical patent/BRPI0408284B1/pt
Publication of BRPI0408284B8 publication Critical patent/BRPI0408284B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)

Abstract

derivados de ftalazinona compostos apresentando fórmula (i): onde a e b jutomados em conjunto representam um anel aromático fundido, opcionalmente substituído; x pode ser nrx ou crxry; se x = nrx então n é 1 ou 2 e se x = crxry então n é 1; rx é selecionado a partir do grupo que consiste em grupos h, alquila c1-20, arila c5-20, heterociclila c3-20, opcionalmente substituídas, amido, tioamido, éster, acila, e sulfonila; ry é selecionado a partir de h, hidróxi, amino; ou rx e ry podem juntos formar um grupo espiro-cicloalquila c3-7 ou heterociclila; rc1 ou rc2 são ambos hidrogênio, ou quando x é crxry, rc1, rc2, rx e ry, em conjunto com os átomos de carbono ao qual são fixados, podem formar um anel aromático fundido opcionalmente substituído; e r1 é selecionado a partir de h e halo.
BRPI0408284A 2003-03-12 2004-03-12 compostos derivados de ftalazinona, seu uso e composição farmacêutica compreendendo os mesmos BRPI0408284B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0305681.9A GB0305681D0 (en) 2003-03-12 2003-03-12 Phthalazinone derivatives
US45499503P 2003-03-14 2003-03-14
US49339903P 2003-08-06 2003-08-06
US52624403P 2003-12-01 2003-12-01
PCT/GB2004/001059 WO2004080976A1 (en) 2003-03-12 2004-03-12 Phthalazinone derivatives

Publications (3)

Publication Number Publication Date
BRPI0408284A BRPI0408284A (pt) 2006-03-07
BRPI0408284B1 BRPI0408284B1 (pt) 2018-12-26
BRPI0408284B8 true BRPI0408284B8 (pt) 2021-05-25

Family

ID=32996122

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408284A BRPI0408284B8 (pt) 2003-03-12 2004-03-12 compostos derivados de ftalazinona, seu uso e composição farmacêutica compreendendo os mesmos

Country Status (22)

Country Link
EP (1) EP1633724B1 (pt)
JP (3) JP4027406B2 (pt)
KR (1) KR101146806B1 (pt)
AU (1) AU2004220321B2 (pt)
BR (1) BRPI0408284B8 (pt)
CA (1) CA2517629C (pt)
CO (1) CO5650256A2 (pt)
CY (1) CY1111597T1 (pt)
EA (1) EA009469B1 (pt)
EC (1) ECSP056094A (pt)
GB (1) GB2415430B (pt)
HK (1) HK1079530A1 (pt)
HR (1) HRP20050895B1 (pt)
IS (1) IS2813B (pt)
LT (1) LTC1633724I2 (pt)
MA (1) MA27758A1 (pt)
MX (1) MXPA05009661A (pt)
NO (2) NO331807B1 (pt)
NZ (1) NZ542680A (pt)
PL (1) PL1633724T3 (pt)
TN (1) TNSN05212A1 (pt)
WO (1) WO2004080976A1 (pt)

Families Citing this family (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60335359D1 (de) 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
GB2415430B (en) * 2003-03-12 2006-07-12 Kudos Pharm Ltd Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0317466D0 (en) * 2003-07-25 2003-08-27 Univ Sheffield Use
CN101693697A (zh) * 2003-07-30 2010-04-14 泽农医药公司 哌嗪衍生物和它们作为治疗剂的用途
SG145745A1 (en) 2003-08-06 2008-09-29 Senomyx Inc Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof
GB0324159D0 (en) 2003-10-15 2003-11-19 Glaxo Group Ltd Novel compounds
PL1684736T3 (pl) * 2003-12-01 2012-01-31 Kudos Pharm Ltd Inhibitory naprawy DNA w leczeniu raka
KR20070057859A (ko) * 2004-08-26 2007-06-07 쿠도스 파마슈티칼스 리미티드 4-헤테로아릴메틸 치환된 프탈라지논 유도체
EP1645556A1 (en) * 2004-10-07 2006-04-12 Boehringer Ingelheim International GmbH Arylpiperazine-benzoylamide derivatives useful as pharmaceutical agents
WO2006084186A2 (en) 2005-02-04 2006-08-10 Senomyx, Inc. Compounds comprising linked hetero aryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions
GB0510142D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
TW200715993A (en) 2005-06-15 2007-05-01 Senomyx Inc Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers
ATE455117T1 (de) * 2005-09-23 2010-01-15 Equispharm Co Ltd 5,6-dimethylthienoä2,3-diüpyrimidinderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzung für die bekämpfung von viren
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
WO2007124152A2 (en) 2006-04-21 2007-11-01 Senomyx, Inc. Comestible compositions comprising high potency savory flavorants, and processes for producing them
US7834015B2 (en) 2006-05-31 2010-11-16 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Pyrrolo[1,2-a] pyrazin-1(2H)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2H)-one derivatives as inhibitors of poly(ADP-ribose)polymerase (PARP)
GB0610680D0 (en) * 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
JP2009539962A (ja) * 2006-06-15 2009-11-19 クドス ファーマシューティカルズ リミテッド Ｐａｒｐ阻害剤としての２−オキシヘテロアリールアミド誘導体
WO2008020180A2 (en) * 2006-08-17 2008-02-21 Kudos Pharmaceuticals Limited Methods of increasing the sensitivity of cancer cells to dna damage
AU2013201880B2 (en) * 2006-10-17 2015-06-25 Kudos Pharmaceuticals Limited Polymorphic form of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
PE20081229A1 (es) * 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
CN101641014B (zh) 2006-12-28 2013-12-18 Abbvie公司 聚（adp-核糖）聚合酶抑制剂
KR20100020981A (ko) * 2007-05-25 2010-02-23 아스트라제네카 아베 암 치료를 위한 ｃｈｋ 및 ｐａｒｐ 억제제의 조합물
WO2008145681A2 (en) 2007-05-31 2008-12-04 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
US20090023727A1 (en) * 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
GB0716532D0 (en) 2007-08-24 2007-10-03 Angeletti P Ist Richerche Bio Therapeutic compounds
NZ585012A (en) 2007-10-03 2012-06-29 Eisai Inc Parp inhibitor compounds, compositions and methods of use
AU2008313467B2 (en) * 2007-10-17 2013-08-29 Kudos Pharmaceuticals Limited 4- [3- (4-cyclopropanecarbonyl-piperazine-1-carbonyl) -4 -fluoro-benzyl] -2H-phthalazin-1-one
CA2704714C (en) 2007-11-15 2018-12-04 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Pyridazinone derivatives as parp inhibitors
CL2008003553A1 (es) * 2007-12-05 2009-11-27 Grindeks Jsc Proceso para preparar atipamezol o clorhidrato de 5-(2-etil-2,3-dihidro-1h-inden-2-il)-1h-imidazol: y loa compuestos intermediarios considerados en el proceso
US8569282B2 (en) 2007-12-11 2013-10-29 Cytopathfinder, Inc. Carboxamide compounds and their use
UY31603A1 (es) * 2008-01-23 2009-08-31 Derivados de ftalazinona
WO2010017055A2 (en) 2008-08-06 2010-02-11 Lead Therapeutics, Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
EP2346495B2 (en) 2008-10-07 2023-05-24 Kudos Pharmaceuticals Limited Pharmaceutical formulation 514
US20120053164A1 (en) 2008-12-19 2012-03-01 Boehringer Ingelheim International Gmbh Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd
US20110015393A1 (en) * 2009-07-15 2011-01-20 Astrazeneca Ab Phthalazinone compound
WO2011030139A1 (en) 2009-09-11 2011-03-17 Astrazeneca Ab 4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
EP2322658A1 (en) 2009-11-13 2011-05-18 Centre National de la Recherche Scientifique (CNRS) Signature for the diagnosis of breast cancer aggressiveness and genetic instability
GEP20146124B (en) 2009-12-17 2014-07-25 Boehringer Ingelheim Int Novel ccr2 receptor antagonists and usage thereof
US8541403B2 (en) * 2010-02-03 2013-09-24 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency
KR101826652B1 (ko) * 2010-02-08 2018-02-07 메디베이션 테크놀로지즈, 인크. 디히드로피리도프탈라지논 유도체의 합성 방법
US8946218B2 (en) 2010-05-12 2015-02-03 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
JP2013526507A (ja) 2010-05-12 2013-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２受容体アンタゴニスト、その製造方法及び薬物としてのその使用
EP2571870B1 (en) 2010-05-17 2015-01-21 Boehringer Ingelheim International GmbH Ccr2 antagonists and uses thereof
JP5636094B2 (ja) 2010-05-25 2014-12-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２受容体アンタゴニスト
WO2011151251A1 (en) 2010-06-01 2011-12-08 Boehringer Ingelheim International Gmbh New ccr2 antagonists
JP2013532683A (ja) * 2010-07-27 2013-08-19 カディラ ヘルスケア リミティド ポリ（ａｄｐリボース）ポリメラーゼ−１阻害剤としての、置換４−（４−フルオロ−３−（ピペラジン−１−カルボニル）ベンジル）フタラジン−１（２ｈ）−オン誘導体
CN102372716A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
SG10201710578TA (en) 2010-10-21 2018-02-27 Medivation Technologies Inc Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt
WO2012071684A1 (en) 2010-12-02 2012-06-07 Shanghai De Novo Pharmatech Co Ltd. Heterocyclic derivates，preparation processes and medical uses thereof
CN103443085B (zh) * 2011-03-14 2016-03-23 南京英派药业有限公司 喹唑啉二酮及其应用
EP2709618A4 (en) * 2011-05-10 2014-11-05 UNIVERSITé LAVAL METHOD FOR THE TREATMENT AND DIAGNOSIS OF PULMONARY ARTERIAL HYPERTENSION
CA2835339A1 (en) 2011-05-18 2012-11-22 Centre National De La Recherche Scientifique (Cnrs) Signature for the diagnosis of cancer aggressiveness and genetic instability
US20140221314A1 (en) * 2011-05-31 2014-08-07 Newgen Therapeutics, Inc. Tricyclic inhibitors of poly(adp-ribose)polymerase
WO2013010839A1 (en) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Novel and selective ccr2 antagonists
RU2665952C2 (ru) 2011-07-22 2018-09-05 Пасилекс Фармасьютикалз Инк. Синтетическая летальность и лечение рака
CN103130723B (zh) * 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
US9790556B2 (en) 2012-01-05 2017-10-17 Centre National De La Recherche Scientifique (Cnrs) Signature for the diagnosis of lung cancer aggressiveness and genetic instability
CN102964354B (zh) * 2012-11-16 2014-08-13 江苏先声药业有限公司 一类噻吩并咪唑衍生物及其应用
ES2614885T3 (es) 2012-12-31 2017-06-02 Cadila Healthcare Limited Derivados sustituidos de ftalazin 1(2H) ona como inhibidores selectivos de la poli(ADP ribosa) polimerasa 1
JP6545148B2 (ja) 2013-03-13 2019-07-17 フラットリー ディスカバリー ラブ，エルエルシー ピリダジノン化合物及び嚢胞性線維症の治療のための方法
WO2014152588A1 (en) * 2013-03-15 2014-09-25 Araxes Pharma Llc Covalent inhibitors of kras g12c
UY35464A (es) 2013-03-15 2014-10-31 Araxes Pharma Llc Inhibidores covalentes de kras g12c.
LT3027598T (lt) * 2013-07-31 2017-06-12 Merck Patent Gmbh Oksochinazolinil-butanamido dariniai
ES2671322T3 (es) * 2013-08-07 2018-06-06 Merck Patent Gmbh Derivados de piperidin urea
KR101670126B1 (ko) 2013-09-13 2016-10-27 일동제약(주) 신규 프탈라지논 유도체 및 그 제조방법
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
CN105985294B (zh) * 2015-02-11 2020-12-25 四川科伦药物研究院有限公司 一种奥拉帕尼的制备方法
ES2898765T3 (es) 2015-04-10 2022-03-08 Araxes Pharma Llc Compuestos de quinazolina sustituidos y métodos de uso de los mismos
EP3283462B1 (en) 2015-04-15 2020-12-02 Araxes Pharma LLC Fused-tricyclic inhibitors of kras and methods of use thereof
CN106146492A (zh) * 2015-04-17 2016-11-23 上海汇伦生命科技有限公司 杂环并咪唑类化合物、其药物组合物及其制备方法和用途
EP3291813A4 (en) * 2015-05-06 2019-01-02 The Regents of The University of California K-ras modulators
US10562886B2 (en) 2015-05-21 2020-02-18 The Regents Of The University Of California Anti-cancer compounds
ES2811098T3 (es) 2015-07-02 2021-03-10 Centrexion Therapeutics Corp Citrato de (4-((3r,4r)-3-metoxitetrahidro-pirano-4-ilamino)piperidin-1-il)(5-metil-6-(((2r, 6s)-6-(p-tolil)tetrahidro-2hpirano-2-il) metilamino)pirimidin-4il) metanona
PL3325662T3 (pl) 2015-07-17 2024-02-26 Pacylex Pharmaceuticals Inc. Wyciszenie epigenetyczne nmt2
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
CN108138177B9 (zh) 2015-07-23 2021-08-13 法国居里学院 Dbait分子与PARP抑制剂的组合用于治疗癌症的用途
WO2017058805A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356353A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058768A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058792A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
CN106554316B (zh) * 2015-09-28 2019-03-08 上海医药集团股份有限公司 一种制备1-[5-[(3,4-二氢-4-氧代-1-酞嗪基)甲基]-2-氟苯甲酰基]哌嗪的方法
WO2017058915A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058902A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058807A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
KR20180081596A (ko) 2015-11-16 2018-07-16 아락세스 파마 엘엘씨 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
TWI730013B (zh) 2015-11-20 2021-06-11 生華生物科技股份有限公司 用於治療癌症的四環喹諾酮類似物組合療法
CZ201682A3 (cs) 2016-02-15 2017-08-23 Zentiva, K.S. Solvatované krystalické formy olaparibu, jejich příprava a použití
WO2017191562A1 (en) * 2016-05-04 2017-11-09 Alembic Pharmaceuticals Limited Process for the preparation of olaparib and polymorphs thereof
SG11201811393WA (en) 2016-06-24 2019-01-30 Univ California Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
CZ2016391A3 (cs) 2016-06-29 2018-01-10 Zentiva, K.S. Farmaceutická formulace olaparibu
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
EP3504196A4 (en) * 2016-08-24 2020-01-22 Scinopharm Taiwan, Ltd. PROCESSES FOR THE PREPARATION OF OLAPARIB
JP2019529484A (ja) 2016-09-29 2019-10-17 アラクセス ファーマ エルエルシー Ｋｒａｓ ｇ１２ｃ変異体タンパク質の阻害剤
WO2018068017A1 (en) 2016-10-07 2018-04-12 Araxes Pharma Llc Heterocyclic compounds as inhibitors of ras and methods of use thereof
CN107955001A (zh) 2016-10-14 2018-04-24 上海汇伦生命科技有限公司 抗肿瘤杂环并咪唑类化合物的药用盐
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
WO2018140514A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
EP3573971A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
JP7327802B2 (ja) 2017-01-26 2023-08-16 アラクセス ファーマ エルエルシー 縮合ヘテロ－ヘテロ二環式化合物およびその使用方法
US11358959B2 (en) 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
WO2018140512A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
WO2018195439A2 (en) 2017-04-20 2018-10-25 The Regents Of The University Of California K-ras modulators
CN110831933A (zh) 2017-05-25 2020-02-21 亚瑞克西斯制药公司 喹唑啉衍生物作为突变kras、hras或nras的调节剂
AU2018271990A1 (en) 2017-05-25 2019-12-12 Araxes Pharma Llc Covalent inhibitors of KRAS
EP3630746A1 (en) 2017-05-25 2020-04-08 Araxes Pharma LLC Compounds and methods of use thereof for treatment of cancer
CA3031777A1 (en) 2018-01-31 2019-07-31 Apotex Inc. Crystalline form of olaparib
CA3088998A1 (en) 2018-02-15 2019-09-06 Senhwa Biosciences, Inc. Quinolone analogs and their salts, compositions, and method for their use
JP2021516229A (ja) * 2018-02-28 2021-07-01 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 低親和性ポリ（ａｄ−リボース）ポリメラーゼ１依存性細胞毒性剤
KR20200130856A (ko) 2018-03-13 2020-11-20 옹쎄오 암 치료에서 획득한 내성에 대한 디베이트 분자
GB201804924D0 (en) * 2018-03-27 2018-05-09 Univ Oxford Innovation Ltd Radiolabelled compound
KR102548191B1 (ko) * 2018-04-09 2023-06-28 상하이테크 유니버시티 표적 단백질 분해 화합물, 이의 항종양 응용, 이의 중간체 및 중간체의 응용
CN112566666A (zh) * 2018-05-14 2021-03-26 努瓦申生物公司 靶向抗癌核激素受体的化合物
CN108558773A (zh) * 2018-05-17 2018-09-21 苏州莱克施德药业有限公司 一种奥拉帕尼药物中间体的制备方法
MX2021013774A (es) 2019-05-14 2021-12-10 Nuvation Bio Inc Compuestos anticancerigenos dirigidos a los receptores hormonales nucleares.
CN114144413A (zh) 2019-07-19 2022-03-04 阿斯利康(瑞典)有限公司 Parp1抑制剂
US11952349B2 (en) 2019-11-13 2024-04-09 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2021140478A1 (en) 2020-01-09 2021-07-15 Astrazeneca Ab Combination therapy for treating cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JP2023537550A (ja) 2020-04-21 2023-09-04 アイディーエンス カンパニー リミテッド フタラジノン化合物の結晶形
CN115485271A (zh) 2020-04-28 2022-12-16 理森制药股份公司 用作聚(adp-核糖)聚合酶（parp）抑制剂的新型化合物
CN111592522B (zh) * 2020-06-17 2022-09-09 郑州大学 一种精氨酸甲基化转移酶5小分子抑制剂及其制备方法和用途
US11795158B2 (en) 2020-06-25 2023-10-24 Astrazeneca Ab Chemical compounds
US12012386B2 (en) 2020-09-16 2024-06-18 Nuformix Technologies Limited Olaparib oxalic acid cocrystals and their pharmaceutical use
WO2022074617A1 (en) 2020-10-09 2022-04-14 Astrazeneca Uk Limited Combination of antibody-drug conjugate and parp1 selective inhibitor
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
CN112500379B (zh) * 2020-12-23 2024-01-23 南京方生和医药科技有限公司 一种奥拉帕利中间体及奥拉帕利的制备方法
US11834458B2 (en) 2021-03-23 2023-12-05 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN113024516B (zh) * 2021-03-29 2022-05-17 中国药科大学 双靶点parp/ezh2抑制剂、制备方法及用途
MX2023011793A (es) 2021-04-08 2023-10-12 Rhizen Pharmaceuticals Ag Inhibidores de poli(adenosin difosfato-ribosa) polimerasa.
US12006314B2 (en) 2021-05-03 2024-06-11 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
JP2024518509A (ja) 2021-05-18 2024-05-01 オンコニック セラピューティクス インコーポレイテッド Ｐａｒｐ阻害剤抵抗性癌治療剤
CN118139624A (zh) 2021-06-02 2024-06-04 阿斯利康(瑞典)有限公司 治疗乳腺癌的方法
KR102645122B1 (ko) 2021-08-25 2024-03-07 주식회사 보령 올라파립의 제조방법
WO2023084311A1 (en) 2021-11-10 2023-05-19 Nuformix Technologies Limited Olaparib hydroxybenzoic acid cocrystals and their pharmaceutical use
AU2022392822A1 (en) 2021-11-18 2024-05-02 Astrazeneca Uk Limited Combination of antibody-drug conjugate and parp1 selective inhibitor
WO2023118085A1 (en) 2021-12-21 2023-06-29 Astrazeneca Ab Methods of treating brain tumours and neuroblastomas
KR20230114646A (ko) * 2022-01-25 2023-08-01 재단법인 한국파스퇴르연구소 벤조다이옥세인 유도체 화합물 및 이의 의약 용도
WO2023156357A1 (en) 2022-02-15 2023-08-24 Astrazeneca Ab Methods of treating prostate cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03003218A (es) * 2000-10-30 2004-12-03 Kudos Pharm Ltd Derivados de ftalazinona.
CA2444531A1 (en) * 2001-05-08 2002-11-14 Kudos Pharmaceuticals Limited Isoquinolinone derivatives as parp inhibitors
DE60335359D1 (de) * 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
GB2415430B (en) * 2003-03-12 2006-07-12 Kudos Pharm Ltd Phthalazinone derivatives

Also Published As

Publication number Publication date
EP1633724A1 (en) 2006-03-15
NO2015008I2 (no) 2015-03-12
KR101146806B1 (ko) 2012-05-22
CA2517629C (en) 2011-07-12
IS2813B (is) 2012-11-15
GB2415430A (en) 2005-12-28
NZ542680A (en) 2008-08-29
WO2004080976A8 (en) 2006-01-05
HRP20050895B1 (hr) 2014-06-06
EA009469B1 (ru) 2007-12-28
JP4027406B2 (ja) 2007-12-26
CA2517629A1 (en) 2004-09-23
LTC1633724I2 (lt) 2016-12-12
MXPA05009661A (es) 2006-03-08
WO2004080976A1 (en) 2004-09-23
TNSN05212A1 (en) 2007-06-11
KR20060054172A (ko) 2006-05-22
AU2004220321B2 (en) 2010-02-25
JP2009079056A (ja) 2009-04-16
HK1079530A1 (en) 2006-04-07
JP2008001718A (ja) 2008-01-10
HRP20050895A2 (hr) 2005-12-31
CO5650256A2 (es) 2006-06-30
PL1633724T3 (pl) 2011-10-31
AU2004220321A1 (en) 2004-09-23
EA200501434A1 (ru) 2006-02-24
BRPI0408284A (pt) 2006-03-07
CY1111597T1 (el) 2015-10-07
IS8052A (is) 2005-09-28
ECSP056094A (es) 2006-03-01
NO20054625D0 (no) 2005-10-07
BRPI0408284B1 (pt) 2018-12-26
JP4268651B2 (ja) 2009-05-27
NO20054625L (no) 2005-11-11
GB2415430B (en) 2006-07-12
JP2006519827A (ja) 2006-08-31
NO331807B1 (no) 2012-04-10
EP1633724B1 (en) 2011-05-04
GB0520754D0 (en) 2005-11-23
MA27758A1 (fr) 2006-02-01
NO2015008I1 (no) 2015-03-23

Similar Documents

Publication Publication Date Title
BRPI0408284B8 (pt) compostos derivados de ftalazinona, seu uso e composição farmacêutica compreendendo os mesmos
ATE508118T1 (de) Phthalazinonderivative
FR17C0003I2 (fr) Steroides comme agonistes de fxr
BR0115478A (pt) Aminotiazós e o uso dos mesmos como antagonistas do receptor da adenosina
HUP0001843A2 (hu) Eljárás nukleozid analógok szintézisére
DK1150944T3 (da) N2-phenylamidinderivater
BR0109855A (pt) Derivados de 8-isoquinolinxantina e 8-quinolixantina como inibidores de pde 5
EA200200360A1 (ru) Производные пурина
EA200101177A1 (ru) Производные индола в качестве антагонистов прогестерона
MX2009013800A (es) Derivados de ftalazinona como inhibidores de parp-1.
TR200002157T2 (tr) Kimyasal bileşikler
NO20026094L (no) Kondenserte azepinderivater og deres anvendelse som antidiuretiske midler
DE60128736D1 (de) Methode zur darstellung von (pyridyl substituierten)methyl-thio-benzimidazol-derivaten
ATE239722T1 (de) Benzofurylpiperazine als serotonin-agonisten
HUP0203603A2 (hu) Új IL-8 receptor antagonista hatású indolszármazékok és ezeket tartalmazó gyógyszerkészítmények
YU72000A (sh) Kompleks platine, njegovo dobijanje i terapeutska primena
KR930703278A (ko) 신규의 디페닐티아졸 유도체
EA200300756A1 (ru) Андрогенные 7-замещенные-11-галогенированные стероиды
BR9812948A (pt) Derivado de 1,2-benzoisotiazol 2-substituìdo, e, uso do composto
BR9811048A (pt) Processo para preparação de um composto
KR860008983A (ko) 4- 벤조일-1- 알킬(알켄일) 피라졸의 제조방법
BR0308890A (pt) Composto
KR910002853A (ko) 도파민 효능제
EA199800693A1 (ru) Азольные соединения с противогрибковой активностью, предназначенные для человека и животных
PT1210346E (pt) Novos alcaloides marinhos activos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: KUDOS PHARMACEUTICALS LIMITED (GB)

B25G Requested change of headquarter approved

Owner name: KUDOS PHARMACEUTICALS LIMITED (GB)

B25G Requested change of headquarter approved

Owner name: KUDOS PHARMACEUTICALS LIMITED (GB)

B25G Requested change of headquarter approved

Owner name: KUDOS PHARMACEUTICALS LIMITED (GB)

B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/12/2018, OBSERVADAS AS CONDICOES LEGAIS.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI NO 52402.004339/2021-99 ORIGEM: 13O VF DO RIO DE JANEIRO PROCESSO NO: 5031296-48.2021.4.02.5101 NULIDADE DE ATO ADMINISTRATIVO AUTOR: LIBBS FARMACEUTICA LTDA. REU(S): KUDOS PHARMACEUTICALS LIMITED (GB) E INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL ? INPI

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/03/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI NO 52402.000848/2022-23 ORIGEM: 20A VARA FEDERAL CIVEL DA SJDF (TRF1) PROCESSO NO: 1089538-57.2021.4.01.3400 ACAO DE PROCEDIMENTO COMUM AUTOR: KUDOS PHARMACEUTICALS LIMITED REU(S): INPI - INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL